Evaluating KRAS mutant allele dosage impact on first-line PDAC outcomes

Higher mutant KRAS dosage linked to worse survival in PDAC patients treated with 1L therapy

INDICATION
Pancreatic
BIOMARKER
KRAS

 

Kaplan-Meier survival curves comparing rwOS by KRAS allele dosage group in pre-treatment samples from PDAC patients anchored on 1L treatment. Median survival times (months) are specified. Log-Rank test P value is indicated.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Visualization showing multiple rows of blue and orange squares, divided by a black dotted line.

Genomic and transcriptomic differences between early-onset and non-early-onset PDAC

2026-07-01
Pancreatic
KRAS
BRCA2
SMAD4
CDKN2A
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Unable to determine image content.

Validating FFPE-based genomic profiling in pancreatic cancer

2025-10-09
Pancreatic
KRAS
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Light green statistical box plot graph on a white background, low contrast.

Characterizing KRAS variants in NSCLC with multimodal RWD

2025-10-09
Lung
KRAS